Sr. Medical Director (Medical & Clinical Affairs)

SCOTT WOSKA PhD candidate, MD, MS

Monterey, California

Email: ********@*****.***

LinkedIn: Scott Woska

Willing to relocate for the right opportunity

Professional Profile Overview

Galen Sports Medicine Orthopedic Institute

Bierun, Poland

October 2023 - Present (Hybrid) Full-time

March 2015 - October 2023 (Hybrid) Part-time

Medical Director, Musculoskeletal/Neurodegenerative Movement Disorders * Regenerative Medicine * Biomechanics Research

Bausch+Lomb Pharmaceuticals

Monterey, California, U.S. (remote)

April 2022 - October 2023

Sr. Medical Director, Medical Affairs/Clinical Affairs/Scientific Oversight

Baxter International, Inc.

Monterey, California (remote)

January 2021 - July 2022

Clinician/Regulatory Subject Matter Expert for Invasive Surgical Device Specialist (Contractor)

IONIS Pharmaceuticals

Monterey, California (remote)

March 2020 - October 2021

U.S./European Senior Clinical Trial Liaison – Project Director (Contractor)

Omeros Corporation

Seattle, Washington (on-site)

January 2019 - August 2019

Medical Director/Medical Affairs

Bausch + Lomb Pharmaceuticals

California/Pacific Northwest/Midwest (remote)

April 2015 - January 2019

Senior Medical Science Liaison

SAMA

Central and Eastern Europe

February 2013 - March 2015

Regional Director, Medical Science Liaison (Contractor/part-time)

January 2012 - February 2013

Medical Science Liaison (Contractor/part-time)

Galen Sports Medicine Orthopedic Institute

Katowice, Poland

2009 - 2013

Attending Orthopedic Residency

Medical University of Silesia Hospital

Katowice, Poland

June 2005 - June 2008

Internal Medicine/General Surgery Residency (Dual residency program in parallel with Orthopedics)

January 2008 - June 2009

Attending Internal Medicine Residency

Galen Sports Medicine Orthopedic Institute

Bierun, Poland

June 2005 - June 2009

Orthopedics Residency (Dual residency program in parallel with Internal Medicine)

AWF University of Physiology and Sport Science

Katowice, Poland

August 2007 - June 2010; August 2012 - June 2013

University Lecturer: Physiology/Exercise Science * Sports Medicine * Sports Nutrition

Medical University of Silesia

Katowice, Poland

September 2005 - July 2008; August 2010 - June 2012

University Lecturer: Physiology * Musculoskeletal/CNS Disorders * Autoimmune Diseases * Orthopedics * Rheumatoid

Galen Orthopedic Sports Medicine

March 2015 – Present (Hybrid)*

Physician, Musculoskeletal and Neurodegenerative Movement Disorders * CV & Metabolic Dysregulation * Regenerative

Medicine * Rehabilitative Biomechanics Research * Exercise Physiologist--Sports Medicine & Nutritional Science

Orthopedic Musculoskeletal, Neurodegenerative, Neuromuscular, and Biomaterial Scaffold Research

Epidemiology Research

Injury Surveillance in Collegiate Athletes

oDeveloped a longitudinal study among elite athletes to assess injury incidence, identify specific risk factors

and patterns, with the objective of proactively developing prevention strategies

Effectiveness of Injury Prevention Strategies in Elite Athletes

oAssessing the effectiveness of neuromuscular training programs and protective equipment in reducing injuries

Musculoskeletal/Neurodegenerative Disorders

oEmpirical analysis of biomaterial scaffolds for orthopedic and neuromuscular disorders

oLeading research on biomaterial scaffolds to treat both neurodegenerative diseases (targeting nerve cell preservation) and neuromuscular disorders (enhancing nerve-muscle connectivity), developing innovative protocols that enhance patient quality of life

oOptimized treatment outcomes for Parkinson’s disease-related movement conditions through meticulous analysis of the efficacy variabilities associated with Botulinum Neurotoxin (BoNT) (Review of the Literature)

oDuchenne Muscular Dystrophy: Epidemiological profile, potential risk factors, and the effectiveness of different therapeutic approaches (Case-Control Study)

oAssessing relationships between early inflammatory biomarkers and heterotopic ossification progression rates in patients with Fibrodysplasia Ossificans Progressiva: A Case-Control Study

oProgression of Multiple System Atrophy relative to other neurodegenerative diseases (Cross-Sectional)

oNeurodegenerative/neuromuscular diagnosis and treatment analysis of Friedreich’s Ataxia, Amyotrophic Lateral Sclerosis, Collagen Type VI Disorder, Multiple System Atrophy, and Duchenne Muscular Dystrophy (Cross-Sectional)

oProgression of osteoarthritis: Identifying early biomarkers and evaluating new treatment modalities

(Longitudinal Cohort Study)

Empirical analysis of biomaterial scaffolds for orthopedic and neuromuscular disorders

Spearheaded biomaterial scaffold research for pediatric musculoskeletal and neuromuscular disorders, developing treatment protocols that improved patient mobility by 30% and reduced recovery time by 40% (Prospective Cohort Study)

Implemented AI, XR, and NLP to optimize surgeon ergonomics and post-surgical patient outcomes

Objectives: Optimize surgical, diagnostic, and treatment outcomes in healthcare delivery

Implement surgical robotics and assess comparative patient outcomes using AI and XR technology

Year One Follow-Up: Patient outcome satisfaction increased 38%

Quality of the physician’s musculoskeletal pain in the back and neck decreased by 49%

Number of physicians with musculoskeletal paint in the back and neck decreased by 82%

Duration of identical surgeries decreased by 21%

Orthopedic Sports Medicine Research

o Effectiveness of USG-guided interventions on neovascularization in Achilles tendinopathy: Predicting Achilles injury months in advance via hypoxic-induced neovessel ingrowth

o Growth factor therapy, PRP, hMSC and tissue engineering applications for enhanced post-injury/post-surgery soft tissue recovery and improved functional outcomes in musculoskeletal injuries and neuro-degenerative movement disorders

o Autologous chondrocyte implantation for treatment of articular cartilage defects in runner’s knees

Research in regenerative medicine, nanoparticles for musculoskeletal disorders, and bioimplants

Exploring minimally invasive techniques utilizing nanoparticles or regenerative medicine approaches for the

treatment of musculoskeletal injuries or degenerative conditions, reducing surgical trauma and recovery times

Investigated the correlation between sport performance and Excess Post-Exercise Oxygen Consumption (EPOC) in

athletes undergoing high-altitude training

Results: Athletes who demonstrate higher EPOC values during high-altitude training for one month showed

17% greater improvements in sea-level endurance performance after returning from altitude

Matrix-induced Autologous Chondrocyte Implantation (ACI), cell-free scaffolds, and induced pluripotent stem cells

Evaluated the efficacy and potential of matrix-induced ACI, cell-free scaffolds, and induced pluripotent stem cells in knee cartilage regeneration and repair

Evidence-based Medical Research: Improving post-op outcomes by controlling inflammatory signatures

hMSC therapy for sports-related injuries vs hMSC + highly concentrated PRP

Sport Science Physiology Research

Diagnosing and treating musculoskeletal injuries related to sports and exercise

Research on Vascular Biomarkers Predictive of Imminent Soft Tissue Injuries – Pioneering Advancements in Injury Prevention and Athlete Performance Optimization

Hyperbaric Chambers for Sports Injuries: Concussions, Chronic Injuries, Compartment Syndrome, Improved

o Aerobic Capacity, Anti-Inflammation, and Delayed Onset of Fatigue

Assessing physiological modulations in persistent use of hyperbaric chambers

oSports Physiology and Performance-based Biomechanics Research

o Physiology of Sports Nutrition and Hydration Pre- and Post-Training (Retrospective Literature Review)

oGlobal networking to establish peer-to-peer research data and information sharing

Case study with 5 penetrating and 5 non-penetrating (“in-frame” mutation) DMD patients

oAim was to compare the clinical outcomes, treatment responses, and quality of life between DMD patients

Management of scoliosis in Duchenne Muscular Dystrophy: 10-year retrospective study in the European Union

Familial Creutzfeldt-Jakob Disease Masquerading as Gerstmann-Sträussler-Scheinker Syndrome: A P102L Mutation Case Study (Presented at Grand Rounds and M&M)

Research (on-going)

oEnhancing surgical tendon-to-bone graft healing using microporous polylactide beads impregnated with peripheral blood implanted in bone tunnels

oAssessing gait analysis and orthopedic interventions to improve mobility in Parkinson's disease

oClinical Research – Neurodegenerative Movement Disorders

Amyotrophic Lateral Sclerosis (ALS)

Strategies to tactically target the SOD1 mutation (A4V) with RNA end-joining technology to reduce the gain of function of the mutated protein

Pediatric Spinal Muscular Atrophy (SMA)

Antisense Oligonucleotide for the treatment of SMA (Meta-Analysis and Systematic Review)

Ataxia Telangiectasia

Coupling deimmunization with synthetic rescue technology to drug the new disease biology

Duchene Muscular Dystrophy

Gene therapy using RNA end-joining technology via intrathecal delivery, requiring a lower viral load and avoids liver toxicity risks associated with intravenous delivery

Oligonucleotide Delivery System for Exon Skipping in DMD (Longitudinal Cohort Study)

*Onsite 3 - 4 weeks per quarter since 2015, contributing to research in orthopedic sports medicine, neuromuscular/neurodegenerative movement disorders, surgical recovery through biomaterial scaffolds, and performance & rehabilitative biomechanics

Biopharmaceutical Profile

Bausch+Lomb Pharmaceuticals

California, U.S. (remote)

April 2022 – October 2023

Sr. Medical Director, Medical Affairs/Clinical Affairs/Scientific Oversight

Medical Affairs Strategy

Significant contribution to the national launch of Miebo™ – the first prescriptive eye drop that targets the

evaporative component of dry eye disease

Orchestrated the Medical Affairs strategy and tactics for clinical and marketed disease state awareness, as

well as post-approval activities for Miebo™. Medical representative for approving all PRC and MRC submissions.

Accountable for global clinical research regulations

oGCP (Good Clinical Practice)

oICH (International Council for Harmonization)

oFDA (U.S. Food & Drug Administration)

oEMA (European Medicines Agency)

oNICE (National Institute for Health and Care Excellence, UK)

oIRB (Institutional Review Board)

Championing ethical conduct and patient safety in clinical trials

oChampioned clinical trial design/execution, ensuring compliance with GCP, FDA, and international regulations

oDeveloped in-house ethical training protocols for training internal and external stakeholders, for enhancing awareness and adherence to GCP standards

oProvided best practices guidance to cross-functional clinical study teams for initiating the Informed Consent Form (ICF) and promoting patient autonomy

oEnsured participant safety, privacy, rights, and dignity by collaborating with IRBs to uphold ethical standards, promote transparency, and foster trust in the medical team by providing open dialogue with trial participants, patient advocacy groups, and clinical trial stakeholders

oEnforced in industry-wide bioethics initiatives, shaping standards for responsible research

Collaborated with Clinical Development in medical documents and preparation/submission of the Investigator’s Brochure (IB), Investigational New Drug (IND) application, and New Drug Application (NDA) for Miebo™

oIND: Forms 1571, 1572 and 3674

oNDA: Forms 356h, 3397, 333, and Guidance Document for e-Submissions

oCSR: Co-evaluated medical review of Individual Case Study Reports (ICSRs) and safety narratives

Medical, Legal, & Regulatory (MLR) Committee

oAccountable for securing Intellectual Property and developing incident response frameworks, safeguarding patient and company data confidentiality, integrity, and safety

oAssessing and defining the company’s risk tolerance and thresholds in relation to cybersecurity materiality, ensuring that planning efforts align with the organization's risk appetite

Efficient budget oversight for Miebo™, ensuring effective financial management and resource allocation

Fully engaged cross-functional alignments with Commercial, PV, Regulatory, Clinical, Legal, CMC, Market

Access and Field Medical teams strategically executed on company objectives with consistent branded messaging

Demonstrated clinical, medical and technical expertise in analyzing and interpreting scientific data, applying strong judgment and problem-solving skill sets to assess relevance in clinical settings

Routinely collaborated with the Medical Communications, Clinical Development, Commercial, Public Relations, and Executive Management teams to plan and execute key scientific communications, encompassing internal/external training, CME/CE programs, podium presentations at congresses, posters, abstracts, and journal publications tailored for the product life-cycle

Monitored the progress of pivotal studies (Phase II and III) against corporate objectives, addressing

variances and emerging risks. Proactively guided the medical team in identifying, communicating, and

resolving issues and challenges, ensuring the study remained on track and achieved its goals.

Provided clinical and scientific development leadership guidance, direction and presentations regarding mechanism of action, pivotal trial outcomes, real world evidence, IITs, and competitive intelligence

Facilitated safety governance meetings with the PV and Clinical Development teams to provide safety

science support for pivotal trial protocol and study designs

Co-managed registration trials and prepared regulatory submissions to support a marketing application

Developed and executed study design and protocols for Phase II – IV

Successfully recruited and trained global PIs to participate in clinical trials (Ph II-IV, IITs, company-sponsored)

Established robust and collaborative international relationships with KOLs, DOLs and thought leaders,

while actively assessing and engaging with the next generation of KOLs

Ensured the medical team supported internal stakeholders in transitioning new drugs and indications

from Phase II into Phase III studies. Provided seasoned leadership and aligned with late-stage

development teams to ensure successful Phase III implementation.

Medical/Scientific Subject Matter Expert on the mechanism of action for the dry eye portfolio, ocular allergy, and antibiotic products, including those in clinical development

Proactively identified and integrated unique perspectives from diverse stakeholders into product

development strategies, fostering innovative approaches and comprehensive solutions

Developed and incorporated refresher training modules for seasoned MSLs and the Commercial team

Accountable for developing de novo training modules for new MSLs and MSL Directors, using emerging technology (AI, XR) and measurable metrics in preparation for the successful commercial launch of Miebo™

Managed and nurtured newly trained MSLs throughout the U.S. in supporting marketed assets in the dry eye space

Developed and executed strategic field medical objectives for pre- and post-launch messaging

oTracked medical and scientific developments within dry eye to inform post-marketing surveillance research opportunities and enhance product value and messaging through evidence generation

oDrove evidence-based product strategies by synthesizing cutting-edge clinical insights, research findings, and

industry thought leadership

oThoroughly evaluated published studies and thought leader interactions to develop insights, deepening the

dry eye market understanding and enhancing the scientific messaging, strategy, and product development

Led a cross-functional task force in strategically targeting Accountable Care Organizations, Digital Opinion

Leaders, and KOLs to aid in developing unique patient-facing educational programs, tools, and resources

Developed and presented scientific and medical expertise with compelling stakeholder presentations,

including national sales team training, unique technology-driven advisory boards, KOL speaker training,

payer memberships, medical education and grant initiatives, and global medical steering committees

Collaborated strategically with the Market Access team to develop and deliver tailored presentations to

payers, resulting in nearly 64% success rate in securing favorable formulary positioning for key products

Unlocked the value proposition for all pharmaceutical products by mastering the business of healthcare,

leveraging expertise in value-based care, cost savings, competitive intelligence, and patient reported

outcomes to drive strategic discussions and shape the future of healthcare delivery

Managed all CE/CME programs, branded webinar initiatives, open-source information, and associated budgets

Evaluated and established Fair Market Value honoraria for all Rx and vision care HCPs per regulatory guidelines

Led bi-weekly cross-functional leadership team meetings to enhance clinical outcomes and corporate

objectives, including strategies for payer and patient advocacy group engagements, and Market Access

initiatives to improve patient access, reduce healthcare costs, and increase market share

KOL Engagement

Developed strategic clinical partnerships with eye care providers in compliance with all applicable regulations

oFrequent engagements with KOLs/TLs/DOLs/micro-influencers to assess data and information gaps

oStrategically targeting next-generation KOLs/DOLs and nurturing those relationships

oInitiated a global steering committee of KOLs to establish Phase II and III study designs and protocols

oDeveloped strategic multi-channel platforms to forge global relationships with medical thought leaders and

patient advocacy groups, advancing medical strategies, identifying data gaps and unmet patient needs

Director, MSL Training-Ophthalmology

Developed de novo training modules and platforms using emerging technologies for newly recruited MSLs

oDeveloped a customized online learning platform tailored to the needs of MSLs

oUpdated all training protocols in compliance with national regulatory agencies and Bausch+Lomb

oSpearheaded self-paced learning modules, virtual simulations, and knowledge assessments to ensure

consistent and effective training across geographical regions

MSL Mentorship and Development

oProvided guidance to new and seasoned MSLs, sharing best practices, strategies for transitioning from

patient care to industry, and fostering a supportive learning environment conducive to professional growth

Initiated beta-testing AI/AR platforms for MSL Training

oEnhancing the training experience, allowing MSLs to immerse themselves in realistic scenarios

oSignificantly advancing the quality of MSL-KOL engagements with real-time feedback to Medical Affairs

Implemented organizational platforms

oCustomizable platforms for MSLs, facilitating centralized storage and rapid retrieval of pertinent information

Medical Content Review and Development

Collaborated closely with PIs to provide strategic guidance and rigorous review in crafting high-impact

manuscripts, ensuring scientific integrity and maximizing the potential for publication success

oCollaborated with the Executive Clinical Director in drafting study designs/protocols

oCo-medical representative for PRC/MRC approvals of public-facing content in alliance with Compliance

oCo-developed and updated Medical, Market Access, and Commercial decks

oDrafted all medically-derived content for video storyboards, always in alignment with promotional team

messaging, including final decisions for voice-over and musical score

Vendor Management

Spearheaded the strategic vetting, recruitment, and comprehensive management of Miebo™ dry eye

accounts across the global Medical Affairs landscape, ensuring seamless execution and optimal stakeholder engagement

oNegotiated and managed vendor MSAs/WOs/POs/budgets with Procurement, Legal and Insurance Risk

oCollaborated with international R&D teams to develop top-tier AI platforms to enhance MSL efficiency

oInternational recruitment of audio-visual vendors for high-speed photography medical videos

oRecruited and trained external stakeholders dedicated to bespoke and interactive advisory boards

Baxter International, Inc.

Monterey, CA U.S. (remote)

January 2021 - July 2022 (Contractor)

Clinician/Regulatory Subject Matter Expert/Invasive Surgical Device Specialist (Contractor)

Sub-specialties: Veritas Collagen Matrix for breast reconstruction

Coupler and Flow Coupler for microsurgical anastomosis during vascular reconstruction

oImplemented Clinical Evaluation Report (CER)/Post Market Surveillance Report (PMSR) Gap Assessments

oReviewed and reassessed IFUs, product claims, and annual progress reports for specified Baxter products

oInitiated comprehensive literature reviews and fully vetted clinical studies cited in CERs

oResponsible for PMSP and PSUR for class IIa, IIb and III CE marked medical devices

oCooperated with Product Design Owners and Medical Writers in developing CE mark regulatory documents

oDetermined the accuracy of indications and claims for products via clinical data and literature reviews

oProvided guidance and subject matter expertise on the remediation team to resolve data gaps

oGenerated aggregate reports (CER, CEP, PMCFP, PMSP, PMS, PMCFER, SSCP, FMEA, and SOTA skeletons)

oProficient in regulatory guidelines including UDI-DI/PI, CE markings, MDD, EUDAMED2, MEDDEV, EUMDR,

MHRA, BfArM, CAPA, IVDR, and PROMs

IONIS Pharmaceuticals

San Diego, CA / Monterey, CA U.S. (remote)

March 2020 - October 2021

U.S./European Senior Clinical Trial Liaison (Contractor)

Subject Matter Expert (Geographic Atrophy, Complement Cascade, dAMD) for internal/external stakeholders

Clinical Development SME leading Phase IIa/b trials for revolutionary subcutaneous antisense therapy targeting complement Factor B in Geographic Atrophy--a breakthrough treatment that modulates the Alternative Pathway to combat dry Age-Related Macular Degeneration (dAMD), representing a new frontier in ophthalmic medicine

Provided medical safety expertise, medical interpretation, and authorship of appropriate sections for clinical documents (protocols and amendments, ICFs, IBs, Signal Evaluation Reports) in collaboration with cross-functional colleagues

Co-facilitated cross-functional Clinical Operations, Clinical Development, and Medical Safety Meetings

Developed bespoke advisory boards and steering committee meetings for internationally recruited Principal Investigators

Yielded individual concierge service to 22 US/25 European investigational teams in providing comprehensive

medical, clinical, and scientific knowledge of the investigational drug (Antisense oligonucleotide), including the

MOA of competitor oligonucleotides (RNAi, antisense RNA, siRNA, Aptamers, miRNA, anti-miRNA, pro-miRNA)

Managed the global cross-functional team leadership and Principal Investigator team meetings

Co-delivered compelling and professionally crafted presentations on oligonucleotide technology to Principal Investigators (PIs), CROs/CRAs, reading centers, and newly recruited clinical investigator teams, highlighting the science, mechanism of action (MOA), and transformative potential of oligonucleotides in treating rare diseases

Enhanced clinical trial processes by leveraging advanced technology, including ePRO eTMF, DDC, Platform trial design, and IXRS to identify optimal predictive analytics for efficient patient screening and randomization, as well as enhancing recruitment and enrollment strategies, resulting in increased overall trial efficiency and accuracy

Delivered guidance to the study teams in operationalizing the engagement strategy during feasibility assessment

Co-facilitated feasibility questionnaire for proposed European clinical sites

Utilized e-Clinical Systems (CTMS, EDC, DSMS) to drive enhanced efficiency and efficacy for the Phase IIa/b trial

Ensured strict compliance with Institutional Review Board (IRB) guidelines for human subject recruitment

Aided in overseeing the implementation of decentralized patient recruitment strategies during the COVID

pandemic, resulting in increased screening and recruitment rates for GA patients to 33% and 35%, respectively

Collaborated with PIs, Duke Reading Center, and CT Coordinators to execute clinical trials from end-to-end

Developed and presented study protocols, clinical data, and unbranded medical GA/Dry AMD pathology slide

decks for educational recruitment programs, university study sites, CROs/CRAs, and investigator meetings

Aided in amending post-COVID SSRPs and PSVs with Clinical Operations--designed to enhance patient screening

Omeros Corporation

Seattle, WA U.S.

January 2019 - August 2019

Medical Director/Medical Affairs

Developed strategic medical imperatives for Rx ocular therapy used in IOL replacement procedures

Omidria (phenylephrine and ketorolac intraocular solution) 1% / 0.3%

oAssisted in leveraging Omidria into the ophthalmic space via FDA transitional Pass-through status

Formal discussions and presentations to Wiley Chamber (Ret. Ophthalmology Medical Officer) at FDA

Played a key role in researching and initiating opportunities for filing Transitional Pass-Through Status under the Hospital Outpatient Prospective Payment System (OPPS)

oTrained KOLs and internal stakeholders on the MOA: Enhanced mydriasis during surgery, reduced surgical

complications and post-op pain after cataract surgery, and improved patient outcomes

Nationally recruited, trained, pollinated, and managed 8 MSLs and 2 National Directors of MSLs

Developed comprehensive onboard training programs for newly recruited MSLs and MSL Directors

Developed and managed the annual Medical Affairs and MSL team budget, ensuring effective resource allocation, managed IIT/Phase IV review processes against research priorities and budget allocation

Ensured the MSLs complied with relevant regulatory requirements, industry guidelines, and company policies

Provided leadership in enhancing and developing team processes, structures, tools, and resources

Oversaw continuing education training for managers to ensure best management practices, career development, and adequate staffing across all project levels

Represented the company at national and regions conferences, medical symposiums, and corporate meetings

Developed and formulated MSL team strategies aligned with corporate and commercial objectives

Aligned MSL activities with business objectives to ensure cohesive therapeutic strategy execution

Established MSL KPIs, expectations, and conducted bi-annual constructive feedback evaluations

Evaluated opportunities for post-marketing surveillance studies—dedicated to a shift in the landscape of

preferred practice patterns: post-operation NSAID + corticosteroid drops

Co-developed pre-clinical and clinical study designs, protocols, ICFs, and facilitated IRB contracts for Phase II-IV

Co-developed impactful advisory boards for inner-circle KOLs using state-of-the-art technology

Managed the Medical Information Request Program and provided timely responses to unsolicited inquiries

Bausch + Lomb Pharmaceuticals

California/Pacific Northwest/Midwest (remote)

April 2015 - January 2019

Senior Medical Science Liaison

Medical and clinical ocular health specialist: Prescription, OTC, and Pipeline Products

Rx Products: Lotemax family Prolensa Besivance Vyzulta Alrex Bepreve Alaway Lacrisert

Istalol Timoptic in Ocudose Macugen Visudyne Retisert Zirgan Zylet Alaway

OTC: PreserVision Ocuvite Lumify Soothe XP

Devices: Field medical lead for training internal/external partners cataract and retina surgical devices, and the MOA of B+L-acquired EyeGate Pharmaceuticals device for treating post-op inflammation/pain in cataract and chronic, and non-infectious uveitis

Stoutly engaged with two Commercial product launches: Vyzulta (glaucoma) Lotemax SM 0.38% (cataract)

Provided comprehensive training and support to internal/external stakeholders for Rx and surgical devices

Regularly presented PRC/MRC-approved medical decks for Vyzulta, Prolensa, Besivance and the Lotemax family

oJournal clubs Symposiums Regional conferences Speaker training NSM P&T committees

MSL Therapeutic Lead and Subject Matter Expert

oPosterior Segment (Retina/Trabecular Meshwork/Glaucoma)

oAnterior Segment (Ocular Surface Diseases)

oOcular Nutritional Supplements (OTC)

Promotional Speaker Trainer for the pathophysiology and MOA of Wet AMD Geographic Atrophy Diabetic

Retinopathy Central Serous Retinopathy Vitreoretinal Diseases related to Ocular Nutrition

SAMA

Central and Eastern Europe

February 2013 - March 2015

Regional Director, Medical Science Liaison (Contractor/part-time)

oRecruited, trained, managed, and mentored a high-performing team of 11 European MSLs for legacy and newly launched products: cardiology (artificial heart valves--mechanical and bioprosthetic, cardiac ablation catheters) * oncology (breast cancer) * endocrinology (metabolic disorders—osteoporosis, Maple Syrup Urine Disease) * dermatology (atopic dermatitis) * rare disease states (short bowl syndrome, DMD, McArdle’s Disease) * cardiovascular (Kawasaki disease) * autoimmune (RA, SLE)

oKey Achievements

Leadership Development

Provided strategic leadership to MSLs, driving personal and professional growth

Achieved a 40% increase in team efficiency and 61% improvement in individual performance, as

measured by MSLS KPI metrics, within the first six months of fostering team growth and development

Performance Metrics

Product knowledge and expertise

Stakeholder

Contact this candidate